LENZ Therapeutics Inc

LENZ▼

Lenz drops as BofA downgrades on slower VIZZ launch

Bank of America downgraded Lenz Therapeutics to Neutral from Buy, citing a slower-than-expected rollout of its presbyopia therapy VIZZ. Analyst Jason Gerberry lowered his price target on Lenz to $7 from $31, essentially valuing the company on its cash days after its Q2 2026 results, which beat consensus estimates earlier this week. Gerberry noted that VIZZ, which the FDA greenlighted in July 2025, added $1.7 million in product sales during Q2, mostly unchanged from the preceding quarter, confirming only modest prescription-volume lift since launch. He reduced his FY26 and peak-sales estimates for the drug to $10 million and $372 million from $25 million and $769 million, respectively. Shares of Lenz Therapeutics slipped for the third consecutive session on Thursday.

LENZ ▼

Seeking Alpha·36dRead more →

LENZ▲

LENZ Therapeutics and Arrotex Pharmaceuticals sign exclusive license deal for VIZZ in Australia and New Zealand

LENZ Therapeutics and Arrotex Pharmaceuticals have entered an exclusive license and commercialization agreement for VIZZ, an aceclidine-based eye drop for presbyopia, in Australia and New Zealand. Under the deal, LENZ will receive an upfront payment and a significant profit share of gross margin from product sales, while Arrotex obtains exclusive rights to register and commercialize VIZZ in those markets. This marks LENZ's fifth commercialization partnership for VIZZ outside the United States, following its FDA approval in July 2025 and U.S. launch in October 2025. Arrotex, Australia's largest pharmaceutical company and part of DBG Health, will leverage its extensive pharmacy network to bring the once-daily, preservative-free treatment to patients. VIZZ is the first and only FDA-approved aceclidine-based eye drop designed to restore near vision for up to 10 hours.

LENZ ▲

GlobeNewswire·86dRead more →